Acne News and Research

Latest Acne News and Research

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study.

8 Dec 2010

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

1 Dec 2010

Syneron launches CO2RE CO2 resurfacing system in US and Canada

Syneron Medical Ltd., the global leader in the medical aesthetic device marketplace, announced today the US Food and Drug Administration (FDA) and Health Canada clearance and commercial launch of its highly flexible CO2RE CO2 resurfacing system. CO2RE is a versatile fractional CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation.

30 Nov 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

AADA releases updated position statement on isotretinoin usage

The American Academy of Dermatology Association (AADA) recently updated its position statement on the use of isotretinoin. The position continues to state that patient safety is dermatologists' primary concern and that the AADA is committed to the safe and responsible use of isotretinoin, which is the most effective treatment for severe acne.

23 Nov 2010

Obagi Medical Products prices secondary offering

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Capital Appreciation 1994 Fund, L.P. and the Zein and Samar Obagi Family Trust, at a public offering price of $10.25 per share.

20 Nov 2010

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

Acne, acne medicine and mental health: Study

Acne drug Accutane (isotretinoin) has been plagued by serious controversies with some linking it to suicidal tendencies. Now the latest research finds that severe acne itself increases the risk for suicidal thoughts and actions, raising more questions about the role of the drug, if any, in suicide.

14 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

12 Nov 2010

New Alma’s Soprano laser technology delivers painless procedure for hair removal

Alma Lasers, Ltd., a leader in laser, light, radiofrequency and ultrasound-based aesthetic devices, unveils the latest in next generation medical laser technology with the debut of its new Soprano(XLi) for laser hair removal and deep dermal heating.

12 Nov 2010

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

9 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

30 Oct 2010

State Watch: R.I. group experiments with payment reform; Ariz. dispute over abortion; Vt. and Feds to end monitoring of caregivers

The Providence (R.I.) Journal: "The Lifespan hospital group and Blue Cross have reached an agreement intended to gradually overturn the way hospital care is financed, with the goal of promoting health, rather than episodes of treatment. The agreement is the first to meet unique-in-the-nation rules from state Health Insurance Commissioner Christopher F. Koller, who has identified hospital costs as the main reason for increases in health-insurance premiums.

30 Oct 2010

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug Administration (FDA).

29 Oct 2010

Acne News and Research

Latest Acne News and Research

Bayer's SAFYRAL oral contraceptive receives FDA approval

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

Syneron launches CO2RE CO2 resurfacing system in US and Canada

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

AADA releases updated position statement on isotretinoin usage

Obagi Medical Products prices secondary offering

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Acne, acne medicine and mental health: Study

NovaBay third quarter net loss increases to $1.6 million

New Alma’s Soprano laser technology delivers painless procedure for hair removal

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

State Watch: R.I. group experiments with payment reform; Ariz. dispute over abortion; Vt. and Feds to end monitoring of caregivers

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Acne News and Research

Latest Acne News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in